Three Scenarios of the Future In Vitro Diagnostics Market: Business-as-Usual, Economic Austerity, Technological Breakthroughs

This new report is designed to help executives develop effective contingency plans that best accommodate uncertainties ahead. The study objectives include:

To identify and evaluate emerging markets and technologies that may present unexpected threats or offer opportunities.

To identify key strategic decisions that will have to be made in the future.

To enhance corporate ability to develop realistic contingency plans.

To prepare executives to accommodate radically different operating climates and reduce surprises.

To challenge accepted perceptions of the future diagnostics market.

This report is an invaluable strategic planning resource for corporate, marketing and R&D executives. The strategic issues explored in the report include:

- How will the future reimbursement changes affect individual market segments?

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export?

- How will the future technological advances affect the major market segment?

- Which companies will enter the market and which will not survive?

These and other key issues facing the decision-makers are explored in this thought-provoking and multi-faceted portrait of the three possible futures and their strategic implication. We would be glad to answer any questions you might have regarding this informative, comprehensive and insightful market research and technology assessment report, and look forward to your subscription.

I. INTRODUCTION
II. EXECUTIVE SUMMARY
A. BUSINESS-AS-USUAL SCENARIO
B. ECONOMIC AUSTERITY SCENARIO
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
III. CONCLUSIONS AND RECOMMENDATIONS
IV.THE SCENARIOS
A. BUSINESS-AS-USUAL SCENARIO
1. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Managed Care
PPOs
HMOs
f. Hospitals
g. Admissions
h. Length of Stay
i. Industry Diversification
j. Physician Demographics
k. Aging Population
Chronic Illnesses
Disease Incidence
Susceptibility to Iatrogenesis
Multiple Illness Cases
l. Laboratory Regulations
m. The FDA Reform
2. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. Centralized Testing
Hospitals
Commercial Laboratories
Blood Banks
Public Health Laboratories
c. Decentralized Testing
Personal Testing
Physician Offices/Group Practices
Ancillary Hospital Locations
- ERs
- ORs
- ICUs/CCUs
Cancer Clinics
Ambulatory Care Centers
Surgery Centers
Nursing Homes
Birth Centers
3. Strategic Implications
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
4. Market Segments
a. Chemistry and Immunoassay
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Histology and Cytology
Introduction
Future Situation
e. Coagulation
Introduction
Future Situation
f. Urinalysis
Introduction
Future Situation
g. Blood Banking
Introduction
Future Situation
5.Technologies
a. Genomics
Introduction
Future Situation
b. Proteomics
Introduction
Future Situation
c. DNA Probes
Introduction
Future Situation
d. Biochips/Microarrays
Introduction
Future Situation
e. Monoclonal Antibodies
Introduction
Future Situation
f. Solid Phase Chemistry
Introduction
Future Situation
g. Biosensors
Introduction
Future Situation
h. Automation and Robotics
Introduction
Future Situation
i. Computer-Aided Diagnosis
Introduction
Future Situation
6.The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Ventures, Mergers and Licensing
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
B. ECONOMIC AUSTERITY SCENARIO
1. Business Environment
a. Socio-Political Climate
Cost-Consciousness
Government Actions
Three-Tier System
Health Rationing
Voucher System
Health IRA
b. Hospital Closures
c. Hospital Utilization
d. Hospital Reorganization
e. Physician Regulations
f. Wellness Programs
g. Corporate Responses
h. Academic Research
2. Outlook for the In Vitro Diagnostics Market
a. Test Utilization
Ordering Practices
Documentation
Recertification
b.Technology Regulations
c. New Laboratory Ventures
d. Computers
e. Industrial Medicine
f. Insurance Companies
g. Test Volume and Market Size
3. Strategic Implications
a. Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.Technologies
Genomics
Proteomics
DNA Probes
Biochips/Microarrays
Monoclonal Antibodies and Immunoassays
Automation and Robotics
Solid Phase Chemistry
Biosensors
Computer-Aided Diagnosis
d.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
1. Business Environment
a. Political/Regulatory Climate
b. R & D Funding
c. Industry-Government Relationship
d. Industry-University Ventures
e.Technological Environment
f. Testing Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
2. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Genomics
c. Proteomics
d. DNA and RNA Probes
e. Biochips/Microarrays
f. Monoclonal Antibodies
g. Immunoassays
h. Information Technology
i. Laboratory Automation and Robotics
j. Solid Phase Chemistry
k. Biosensors
l. Holography
m. Pharmaceuticals
3. Strategic Implications
a.Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
Test Volume and Market Size
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
V.APPENDICES: METHODOLOGY
A.The Delphi
B. Cross-Impact Analysis
C. Substitution Modeling

Executive Summary Table I: Business-As-Usual
Scenario, Growth Areas in Clinical Laboratory
Testing
Executive Summary Table II: Economic Austerity
Scenario, Growth Areas in Clinical Laboratory
Testing
Executive Summary Table III: Technological
Breakthroughs Scenario, Growth Areas in
Clinical Laboratory Testing
Executive Summary Table IV: Market Size by Location
Executive Summary Table V: Market Size by Laboratory
Discipline
Table-1: Business-As-Usual Scenario, Health
Care Costs by Expenditure Type
Table-2: Business-As-Usual Scenario, HMO and PPO
Enrollment
Table-3: Business-As-Usual Scenario, Selected
Hospital Statistics
Table-4: Business-As-Usual Scenario,Total Population
and Physician Demographics
Table-5: Business-As-Usual Scenario,Test Volume
by Location
Table-6: Business-As-Usual Scenario,Test Distribution
by Location
Table-7: Business-As-Usual Scenario, Market Size
by Location
Table-8: Business-As-Usual Scenario,Typical
Pre-Admission Tests
Table-9: Business-As-Usual Scenario,Test Volume
by Laboratory Discipline
Table-10: Business-As-Usual Scenario, Market Size
By Laboratory Discipline
Table-11: Economic Austerity Scenario, Selected
Hospital Statistics
Table-12: Economic Austerity Scenario,
HMO and PPO Enrollment
Table-13: Economic Austerity Scenario,Total Population
and Physician Demographics
Table-14: Economic Austerity Scenario, Major
Categories of Overutilized Tests
Table-15: Economic Austerity Scenario,
Test Volume by Location
Table-16: Economic Austerity Scenario,Test
Distribution by Location
Table-17: Economic Austerity Scenario,
Market Size by Location
Table-18: Economic Austerity Scenario,Timing
Requirements for Selected Laboratory Tests
Table-19: Economic Austerity Scenario,Test Volume
by Laboratory Discipline
Table-20: Economic Austerity Scenario, Market Size
by Laboratory Discipline
Table-21: Technological Breakthroughs Scenario, HMO
and PPO Enrollment
Table-22: Technological Breakthroughs Scenario,Total
Population and Physician Demographics
Table-23: Technological Breakthroughs Scenario,
Selected Hospital Statistics
Table-24: Technological Breakthroughs Scenario,
Test Volume by Location
Table-25: Technological Breakthroughs Scenario,
Test Distribution by Location
Table-26: Technological Breakthroughs Scenario,
Market Size by Location
Table-27: Technological Breakthroughs Scenario,
Test Volume by Laboratory Discipline
Table-28: Technological Breakthroughs Scenario,
Market Size by Laboratory Discipline

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available